Sun Pharma Advanced Research Company share news, announcements and annual reports
NSE: SPARCBSE: 532872Pharmaceuticals & BiotechnologySmall Cap
Sun Pharma Advanced Research Company Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2007
Last close ₹176.46down ₹6.52 (3.56%)BSE ₹176.90
Share price at the NSE close on 30 Oct 2026. Previous close ₹182.98.
30 Oct: open ₹183.90, high ₹183.90, low ₹175.25
52-week range of traded prices to 30 Oct 2026
₹108.00Low, 23 Mar 2026₹289.00High, 8 Jul 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,727 Cr778th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 3.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.28
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 118.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 84.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.42
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,50,81840.4% delivered
Sun Pharma Advanced Research Company share news and announcements
577 announcements, routine notices left out, newest first. Page 2 of 12.
Jul 2025
5 Jul · General Updates
Jun 2025
23 Jun · Legal
Exchange has sought clarification from Sun Pharma Advanced Research Company Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted declaration in case of unmodified opinion(s) The response of the Company is awaited.3 Jun · General Updates
May 2025
30 May · Legal
The exchange asked on 28 May 2025
29 May · Legal
19 May · Results
19 May · Results
12 May · Board meeting
Apr 2025
Mar 2025
25 Mar · Legal
The exchange asked on 25 Mar 2025
5 Mar · Rating
Feb 2025
10 Feb · Results
10 Feb · Board meeting
10 Feb · Results
Jan 2025
31 Jan · Board meeting
17 Jan · Management
Dec 2024
Nov 2024
26 Nov · Legal
The exchange asked on 22 Nov 2024
4 Nov · Results
4 Nov · Board meeting
Oct 2024
25 Oct · Board meeting
Aug 2024
5 Aug · Results
5 Aug · Business
5 Aug · Board meeting
Jul 2024
29 Jul · Board meeting
18 Jul · Meeting
15 Jul · Management
15 Jul · Management
Jun 2024
May 2024
24 May · Business
24 May · Management
24 May · Board meeting
24 May · Results
Apr 2024
10 Apr · Business
Feb 2024
14 Feb · Analysts